Atlastin 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{infobox-protein
| protein_name = Atlastin-1
| gene = ATL1
| uniprot_id = Q9Y2L9
| pdb_ids = 3W6G, 3W6H, 4IDN
| molecular_weight = ~64000 Da
| subcellular_localization = Endoplasmic reticulum membrane
| protein_family = Atlastin/SPATA5 AAA ATPase family
}}
Atlastin-1 is a membrane-bound GTPase encoded by the ATL1 gene. Atlastin-1 is essential for establishing and maintaining the structure of the endoplasmic reticulum (ER) network. Mutations in ATL1 cause hereditary spastic paraplegia (SPG3A), the second most common form of autosomal dominant HSP.
| Domain | Residues | Function |
|---|---|---|
| N-terminal GTPase domain | 1-200 | GTP binding and hydrolysis |
| Linker region | 201-350 | Domain organization |
| Transmembrane domains | 351-450 | ER membrane anchoring (3 TM helices) |
| C-terminal helix | 451-500 | Membrane association |
| Feature | Motif | Function |
|---|---|---|
| GXXXXGK[S/T] | Walker A | ATP/GTP binding |
| hhhhDE | Walker B | Hydrolysis |
| NKXD | Switch I | GTP binding |
| T[GTP]X | Switch II | Conformational changes |
Atlastin-1 drives ER network formation:
| Function | Mechanism |
|---|---|
| ER shape | Establishes peripheral ER sheets and tubules |
| ER connectivity | Creates network topology |
| Axonal function | Maintains axonal ER |
| ER-Golgi trafficking | Participates in secretory pathway |
| Calcium homeostasis | ER calcium storage |
| Aspect | Details |
|---|---|
| Inheritance | Autosomal dominant |
| Prevalence | ~10% of autosomal dominant HSP |
| Mutations | Over 50 pathogenic variants |
| Onset | Often childhood (youngest HSP) |
Pathogenic Mechanisms:
ATL1 mutations can cause HSN1:
| Strategy | Status | Description |
|---|---|---|
| Gene therapy | Preclinical | AAV-ATL1 delivery |
| ER stress modulators | Research | Chemical chaperones |
| GTPase activators | Research | Enhancing function |
| Neuroprotective agents | Research | General neuroprotection |
Zhao X, et al. (2001). "Mutations in atlastin cause HSP." Nat Genet 29(3):326-331. PMID:11685205
Finkel RS, et al. (2014). "ATL1-related HSP." Neurology 83(13):1158-1165. PMID:25186858
Sakata K, et al. (2020). "ATL1 and ER morphology." J Cell Biol 219(5):e201905078. PMID:32211852
Kornak U, et al. (2014). "ATL1 and HSP." Brain 137(Pt 4):1034-1046. PMID:24585494
Wang L, et al. (2021). "ER morphology in ATL1 mutants." Nat Commun 12(1):2736. PMID:33990572
Beetz C, et al. (2013). "ATL1 mutation screening." Neurology 81(16):1365-1371. PMID:24049173
Hu J, et al. (2019). "Therapeutic approaches for SPG3A." Neurotherapeutics 16(3):661-674. PMID:31140032
Shen PY, et al. (2022). "ATL1 and axonal ER." Trends Neurosci 45(9):678-689. PMID:35945321
The study of Atlastin 1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.